Drug intelligence / Profile preview

UIO 524

Development stage: Preclinical
Lead developer: TransCode Therapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intravesical

Overview

UIO 524 is a genetically-engineered oncolytic adenovirus developed for cancer immunotherapy. Originally part of a preclinical program at Unleash Immuno Oncolytics, it was subsequently licensed by TransCode Therapeutics for further development. The agent is designed to selectively infect and replicate within tumor cells, leading to direct cell lysis and the subsequent release of tumor-associated antigens. This process is intended to stimulate a systemic anti-tumor immune response. UIO 524 is being investigated primarily for the treatment of muscle-invasive bladder cancer (MIBC).

Beyond the preview

Go deeper on UIO 524.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UIO 524.

Explore the full profile